Navigation Links
Mayo Clinic researchers: Insulin-boosting medication does not impair ability to survive heart attack
Date:11/5/2007

ORLANDO, Fla. -- Mayo Clinic researchers helped clarify a growing concern about the link between diabetes mellitus treatments and heart attack with the first large, population-based study showing that a group of common medications does not reduce diabetic patients heart attack survival rates. These results were presented today at the American Heart Associations Scientific Sessions 2007 in Orlando, Fla.

The drugs studied are called sulfonylureas and include several commonly used pills to increase insulin release to lower blood sugar. Second-generation sulfonylureas -- known collectively as SU2 -- include glimepiride (Amaryl), glipizide (Glucotrol, Glucotrol XL), and glyburide (DiaBeta, Micronase, Glynase).(1)

Significance of the Mayo Clinic Study

The prevalence of diabetes mellitus is growing rapidly, and physicians need evidence for their treatment recommendations. Worldwide, the number of diabetics is projected to more than double in three decades, from 171 million in 2000 to 366 million in 2030.(2) Many patients with diabetes are at increased risk for heart failure. This complicates their treatment, and has raised concern in recent years among some physicians that SU2s may impair the hearts ability to withstand stress, thus reducing patients ability to survive heart attacks, says Veronique Roger, M.D., M.P.H., the Mayo cardiologist and epidemiologist who led the study.

The Mayo study is the first to use a broad population of community members to extract information about the impact of various diabetes treatments on patients health after heart attack. The Mayo group evaluated the outcome of heart attack in two groups: people who had diabetes and those who did not. Group members were similar in terms of age, gender and lifestyle habits such as smoking. In the diabetes group, researchers tracked patient outcome after heart attack in patients taking three different treatment approaches to lowering blood sugar: SU2 dr
'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Radiologists encouraged to look beyond cancer for clinically unseen diseases
3. Clinical depression linked to abnormal emotional brain circuits
4. Preclinical study suggests organ-transplant drug may aid in lupus fight
5. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
6. AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic
7. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
8. MinuteClinic Becomes Participating Provider with Assurant Health
9. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
10. Acupuncturists Relocation Tightens Relationship With Fertility Clinic
11. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... York, New York (PRWEB) August 01, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) on behalf of women who allegedly experienced ... of power morcellators in gynecological surgeries, Bernstein Liebhard LLP ... to withdraw a number of power morcellators marketed by ... a report from The New York Times, some critics ...
(Date:8/1/2014)... benefits of a cancer diagnosis may improve health outcomes ... conducted by a researcher at the University of Houston ... writing intervention is the writing instruction. Otherwise, writing is ... a journal can be therapeutic, but oftentimes we don,t ... or not," said Qian Lu, assistant professor and director ...
(Date:8/1/2014)... August 01, 2014 On Monday, June ... NextGen User Symposium in San Francisco, CA. Now in ... the JW Marriott Union Square hotel. , “We are ... up to speed with ACA compliance issues,” Quirk Healthcare ... The symposium provides attendees guidance with NextGen implementation and ...
(Date:8/1/2014)... August 01, 2014 According to ... by Geography (Asia-Pacific, North America, Europe, & ROW), ... by Fuel Type (Gasoline & Diesel), by After-Treatment ... - Trends & Forecasts to 2019", defines and ... an analysis of major countries in all the ...
(Date:8/1/2014)... Scientists at Albert Einstein College of Medicine ... aid in digestion help keep the intestinal lining intact. ... , could yield new therapies for inflammatory bowel disease ... The research involved the intestinal microbiome, which contains some ... promoting or preventing disease is a major emerging field ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:'Normal' bacteria vital for keeping intestinal lining intact 2
... scientists implicates a new protein in obesity development and highlights ... resistance. Jorge Moscat, PhD, chair of UC,s ... ERK are involved in adipogeneis, (the development of adipocytes, or ... works together. The study is published online in ...
... , BOULDER, Colo. , ... of Functional Fitness on Walk the Talk ... Sam Iannetta , a champion powerlifter, tells—and shows—how ... healing injuries, whatever your fitness practice: yoga, cycling, ...
... SHANGHAI , Feb. 12 General Nutrition ... announced today that it, together with its parent company, has entered ... Bright Food (Group) Co., LTD (Bright Food). The partnership, to be ... market. Bright Food , a leading state-owned conglomerate in ...
... received male donors, plasma had worse outcomes, study found ... blood-banking industry discourages transfusing the blood product known as ... reaction in the recipients. , But now researchers have ... have advantages. , Plasma is the fluid in ...
... Touching down toe-first is less economical in humans, research shows , ... to walk heel-first than to walk on the balls of your ... Compared with heel-first walking, it takes 83 percent more energy to ... on the balls of your feet, according to the University of ...
... ... has just released their emWave® Desktop product. emWave Desktop works on both PC and ... ... has just released their emWave® Desktop product. emWave Desktop works on both PC and ...
Cached Medicine News:Health News:Research highlights role of protein pair in obesity regulation 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 3Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 4Health News:Restrictions on Plasma From Female Donors May Need Revisiting 2Health News:Heel-First Walking Conserves Energy 2Health News:HeartMath Announces the Release of Their New emWave Desktop Software 2Health News:HeartMath Announces the Release of Their New emWave Desktop Software 3Health News:HeartMath Announces the Release of Their New emWave Desktop Software 4
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. Wedbush Life ... Wednesday, August 13, 2014 at 9.10 a.m. Eastern Time ... York, NY Thursday, September 4, 2014 at 8.30 ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:7/31/2014)... 31, 2014  UBM Medica US announces that ... for oncologists, presents exclusive slide shows dealing with communication ... quality cancer care. Cancer Network, ... offers news, blogs, and podcasts about the latest clinical ... care: , End-of-life care is challenging for ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Cepheid to Webcast Upcoming Financial Presentations 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
... , NEW YORK, Dec. 7 ... updated efficacy and safety data as well as new ... in combination with bortezomib (Velcade(R)) (+/- dexamethasone) in patients ... "A Multicenter Phase 1/2 Study Evaluating the Safety and ...
... , ENGLEWOOD, Colo., Dec. 7 ... system, DoseEdge(TM), during this week,s ASHP Midyear Clinical Meeting ... patient safety and pharmacy efficiency through the management of ... easily into current pharmacy practice and techniques, while providing ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: